Definium Therapeutics (DFTX) Other financing activities (2021 - 2026)

Definium Therapeutics (DFTX) has 6 years of Other financing activities data on file, last reported at $1.2 million in Q1 2026.

• On a quarterly basis, Other financing activities rose 404.64% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $259.8 million, a 4.54% increase from a year earlier, with the FY2025 full-year figure at $258.9 million, up 3.54% from the prior year.
• Other financing activities for Q1 2026 stood at $1.2 million, down from $257.9 million in the prior quarter.
• Over the last five years, Other financing activities for DFTX reached as high as $257.9 million in Q4 2025 and fell as low as -$688000.0 in Q4 2023.
• Historically, Other financing activities has averaged $43.9 million across 5 years, with a median of $1.0 million in 2025.
• Across the five-year window, Other financing activities sank 104.04% in 2023 and soared 35793.02% in 2024, its largest moves.
• Year by year, Other financing activities stood at $17.0 million in 2022, then sank by 104.04% to -$688000.0 in 2023, then surged by 35793.02% to $245.6 million in 2024, then grew by 5.0% to $257.9 million in 2025, then sank by 99.54% to $1.2 million in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $1.2 million in Q1 2026, $257.9 million in Q4 2025, and $818000.0 in Q3 2025.